Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Cash and Equivalents of $11.44 million for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.44M | -36.3% |
| 2024 | $17.96M | -2.0% |
| 2023 | $18.32M | -7.3% |
| 2022 | $19.76M | -26.9% |
| 2021 | $27.04M | +9.2% |
| 2020 | $24.75M | -12.3% |
| 2019 | $28.21M | +1.0% |
| 2018 | $27.94M | -38.5% |
| 2017 | $45.41M | +31.6% |
| 2016 | $34.51M | -9.7% |
| 2015 | $38.20M | -4.2% |
| 2014 | $39.87M | -2.5% |
| 2013 | $40.87M | -24.8% |
| 2012 | $54.35M | -23.0% |
| 2011 | $70.60M | +7.1% |
| 2010 | $65.89M | -16.3% |
| 2009 | $78.70M | +565.3% |
| 2008 | $11.83M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.20M | -13.0% | -5.5% |
| June 30, 2025 | $16.09M | -7.2% | +6.5% |
| March 31, 2025 | $15.11M | -18.5% | -15.9% |
| December 31, 2024 | $17.96M | -2.0% | +2.9% |
| September 30, 2024 | $17.46M | -5.6% | +0.7% |
| June 30, 2024 | $17.34M | -5.0% | -6.5% |
| March 31, 2024 | $18.55M | +13.2% | +1.2% |
| December 31, 2023 | $18.32M | -7.3% | -1.0% |
- CUMBERLAND PHARMACEUTICALS INC showed a decrease of -36.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, CUMBERLAND PHARMACEUTICALS INC’s cash and equivalents has declined by 3.3% (from $11.83 million to $11.44 million).
- The most recent figure is from CUMBERLAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: